Serum Lipoprotein(a) as Predictive Factor for Early Neurological Deterioration of Acute Ischemic Stroke After Thrombolysis
Ruiming Wang,Weiguo Kong,Wenhua Zhang
DOI: https://doi.org/10.2147/ijgm.s475767
IF: 2.145
2024-09-03
International Journal of General Medicine
Abstract:Ruiming Wang, Weiguo Kong, Wenhua Zhang Department of Neurology, Hangzhou Traditional Chinese Medicine Hospital Affiliated to Zhejiang Chinese Medical University, Hangzhou, People's Republic of China Correspondence: Wenhua Zhang, Department of Neurology, Hangzhou Traditional Chinese Medicine Hospital affiliated to Zhejiang Chinese Medical University, Hangzhou, People's Republic of China, Tel +86-571-85827888, Fax +86-571-85119481, Email Objective: This study aimed to explore the relationship between serum lipoprotein(a) (LP(a)) levels and early neurological deterioration (END) in patients with acute ischemic stroke (AIS) after thrombolysis. Methods: In total, 236 patients with AIS after thrombolysis were enrolled in this study. Serum LP(a) levels were measured on admission after thrombolysis. END was defined as an increase of at least two points in the NIHSS score within 48 hours after thrombolysis. Binary logistic regression analysis was used to assess the association between serum LP(a) levels and END. Results: Overall, patients with END had higher LP(a) than those without END (high LP(a): 38.3% vs 22.2%, intermediate LP(a): 40.3% vs 41.8%, low LP(a): 21.3% vs 36.0%, p< 0.005). In the multivariate analysis, high LP(a) (defined as LP(a) level ≥ 300 mg/L) was an independent risk factor for END post-thrombolysis (OR=3.154, 95% CI=1.067– 9.322, p=0.038). Conclusion: Our findings demonstrated that LP(a) was an independent risk factor for END post-thrombolysis and that LP(a) level ≥ 300 mg/L could be associated with END post-thrombolysis in this study population. Keywords: Lipoprotein(a), early neurological deterioration, acute ischemic stroke, thrombolysis Acute ischemic stroke (AIS) remains a leading cause of disability and mortality globally. 1 Although thrombolysis provides an opportunity to recover cerebral blood flow and perfusion, 2 the outcomes after thrombolysis are not always positive in all patients. Some AIS patients still suffer from early neurological deterioration (END) even after thrombolysis, which could lead to poor clinical outcomes. 3 Besides obvious causes like intracerebral hemorrhage and malignant edema, previous study suggested female sex, hypertension, diabetes, and smoking, were associated with END. 4 In clinical practice, treating END may involve strategies such as plasma volume expansion, induced hypertension and enhanced antithrombotic therapy, though none have been definitively validated to date. 5 Recent research has shown that the use of argatroban and tirofiban could be helpful in the prevention of END in AIS. 5,6 Therefore, it is important to explore the risk factors of END to facilitate early intervention. The pathophysiological mechanism of END post-thrombolysis remains unclear; some reports suggest that hemodynamic changes due to thrombus extension could be a possible cause. 7 Lipoprotein(a) [LP(a)] is associated with the occurrence, recurrence, and prognosis of AIS. 8,9 Research has suggested that elevated serum LP(a) level are associated with inflammation, atherosclerosis, and thrombus formation, 10 suggesting a possible link between LP(a) and the mechanisms underlying END post-thrombolysis. However, the relationship between LP(a) levels and risk of END post-thrombolysis remains unknown. By researching this relationship, our study aimed to identify the role of LP(a) as a predictive biomarker for END, offering insights into the pathophysiological mechanisms of END post-thrombolysis, and potential strategies to reduce this risk. This was a single-center observational study. AIS was diagnosed according to criteria set forth by the World Health Organization. Consecutive patients with AIS who were admitted to our hospital with voluntary participation in this study were enrolled between February 2021 to November 2023. The inclusion criteria were as follows: (1) age ≥18 years; (2) thrombolysis treatment (alteplase, 0.9 mg/kg up to a maximum of 90 mg, 10% of the total dosage as a bolus, and the rest for 1 hour); (3) blood samples collected within the first 24 h following the onset of stroke; (4) completed computed tomography (CT) /magnetic resonance imaging (MRI) scans to confirm the diagnosis. The exclusion criteria were as follows: (1) patients without laboratory test data; (2) endovascular interventions; (3) patients with severe chronic diseases or cancer before stroke onset. All subjects provided written informed consent prior to the study, and the protocols were approved by the ethics committee of the Hangzhou Traditional Chinese Medicine Hospital affiliated to Zhejiang Chinese Medical University. All clinical investigations were conducted in accordance with the prin -Abstract Truncated-
medicine, general & internal